Concord Biotech Limited Fundamental Analysis
Concord Biotech Limited (CONCORDBIO.BO) shows moderate financial fundamentals with a PE ratio of 51.68, profit margin of 24.68%, and ROE of 13.94%. The company generates $10.5B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 91.1/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze CONCORDBIO.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentCONCORDBIO.BO demonstrates superior asset utilization.
Valuation Score
ModerateCONCORDBIO.BO shows balanced valuation metrics.
Growth Score
ModerateCONCORDBIO.BO shows steady but slowing expansion.
Financial Health Score
ExcellentCONCORDBIO.BO maintains a strong and stable balance sheet.
Profitability Score
ModerateCONCORDBIO.BO maintains healthy but balanced margins.
Key Financial Metrics
Is CONCORDBIO.BO Expensive or Cheap?
P/E Ratio
CONCORDBIO.BO trades at 51.68 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CONCORDBIO.BO's PEG of -1.72 indicates potential undervaluation.
Price to Book
The market values Concord Biotech Limited at 6.69 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 33.63 times EBITDA. This signals the market has high growth expectations.
How Well Does CONCORDBIO.BO Make Money?
Net Profit Margin
For every $100 in sales, Concord Biotech Limited keeps $24.68 as profit after all expenses.
Operating Margin
Core operations generate 32.31 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.94 in profit for every $100 of shareholder equity.
ROA
Concord Biotech Limited generates $11.65 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Concord Biotech Limited produces operating cash flow of $1.51B, showing steady but balanced cash generation.
Free Cash Flow
Concord Biotech Limited produces free cash flow of $972.72M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $9.30 in free cash annually.
FCF Yield
CONCORDBIO.BO converts 0.73% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
51.68
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.72
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.69
vs 25 benchmark
P/S Ratio
Price to sales ratio
12.74
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.001
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.39
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.14
vs 25 benchmark
ROA
Return on assets percentage
0.12
vs 25 benchmark
ROCE
Return on capital employed
0.16
vs 25 benchmark
How CONCORDBIO.BO Stacks Against Its Sector Peers
| Metric | CONCORDBIO.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 51.68 | 29.63 | Worse (Expensive) |
| ROE | 13.94% | 223.00% | Weak |
| Net Margin | 24.68% | -38669.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 7.39 | 4.30 | Strong Liquidity |
| ROA | 11.65% | -379.00% (disorted) | Strong |
CONCORDBIO.BO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Concord Biotech Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation